Concepedia

James J. Rusthoven

JJ

39

Publications

5.6K

Citations

27

H-Index

1978

Active since

Affiliations

Ontario Institute for Cancer Research(Current)

Eli Lilly (United States)

McMaster University

Princess Margaret Cancer Centre

Hamilton Regional Laboratory Medicine Program

James J. Rusthoven is an author at Ontario Institute for Cancer Research specializing in medicine, oncology, and pathology.

Top concepts

Publications per year

1978–2023

39

Publications

39

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3K citations

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B<sub>12</sub> as Front-Line Therapy in Malignant Pleural Mesothelioma

Giorgio V. Scagliotti, Dong-M. Shin, Hedy L. Kindler et al. · Journal of Clinical Oncology · 2003 · 255 citations

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2023 · 251 citations

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Clet Niyikiza, Sharyn D. Baker, David E. Seitz et al. · PubMed · 2002 · 247 citations

, , +11

Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

James J. Rusthoven, Elizabeth A. Eisenhauer, Charles Butts et al. · Journal of Clinical Oncology · 1999 · 218 citations

Rows per page

1–5 of 39